Successful Treatment of Early Post-Transplant Bloodstream and Pulmonary Infection Caused by Carbapenem-Resistant Klebsiella pneumoniae With a Combination of Ceftazidime-Avibactam and Carbapenem: A Case Report

被引:12
|
作者
Wang, Zhiqiang [1 ]
Ma, Ke [2 ]
Chen, Zhongju [3 ]
Guo, Zhiliang [1 ]
Zhao, Guangyuan [1 ]
Guo, Hui [1 ,4 ]
Zhu, Lan [1 ,4 ]
Chen, Gang [1 ,4 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Inst Organ Transplantat, Wuhan, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Infect Dis, Wuhan, Peoples R China
[3] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Lab Med, Wuhan, Peoples R China
[4] Chinese Acad Med Sci, Key Lab Organ Transplantat, Minist Publ Hlth, Minist Educ, Beijing, Peoples R China
关键词
MORTALITY; OUTCOMES; ORGANS;
D O I
10.1016/j.transproceed.2020.08.006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Bloodstream infection with carbapenem-resistant Klebsiella pneumoniae (CRKP) is a severe and challenging complication in the early post-transplantation period. Pulmonary infection secondary to sepsis caused by CRKP has been reported only rarely in kidney transplant recipients. Here we report an interesting and complicated case in which CRKP was initially isolated in a culture of renal graft preservation solution, yet was not detected in the daily cultures from collection of surgical drainage. Prophylactic tigecycline was terminated at post-transplantation day 10 because of the occurrence of acute pancreatitis. Five days later, the patient suddenly developed a multisite infection with CRKP involving the bloodstream, urinary tract, and lungs, indicating probable transmission from the donor. Fortunately, the infection was controlled quickly and effectively with a combination therapy consisting of ceftazidime-avibactam (CZA) and carbapenem, which was suggested by the results of disc diffusion susceptibility testing. However, the CRKP infection reappeared in the bloodstream and urinary tract soon after the treatment of acute rejection. The combination regimen was continued for another 15 days, and the patient ultimately recovered. During the following 15 months of observation, the patient's renal graft function remained stable, without recurrence of the CRKP infection. In conclusion, the combined use of CZA and carbapenem was safe and produced an optimal therapeutic effect on the severe multisite infection caused by CRKP in a renal transplant recipient, thus providing a reference case for treating such patients.
引用
收藏
页码:2742 / 2746
页数:5
相关论文
共 50 条
  • [21] In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates
    Hosbul, Tugrul
    Aydogan, Canset Nur
    Kaya, Sinem
    Bedir, Orhan
    Gumral, Ramazan
    Albay, Ali
    MIKROBIYOLOJI BULTENI, 2022, 56 (02): : 218 - 229
  • [22] Ceftazidime-Avibactam resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae: A phenotypic and genotypic analysis
    Krithika, Varshini M.
    Ganesan, Vithiya
    Rajendran, T.
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2024, 49
  • [23] Disseminated organ and tissue infection secondary to carbapenem-resistant Klebsiella pneumoniae bloodstream infection for acute lymphoblastic leukemia treated with ceftazidime-avibactam: Two case reports
    He, Mingxia
    Jiang, Yuxia
    Wu, Haiying
    Xu, Xiaofeng
    Jiang, Huifang
    MEDICINE, 2025, 104 (02)
  • [24] Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China
    Zhang, P.
    Shi, Q.
    Hu, H.
    Hong, B.
    Wu, X.
    Du, X.
    Akova, M.
    Yu, Y.
    CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (01) : 124.e1 - 124.e4
  • [25] Ceftazidime/Avibactam, Polymyxin or Tigecycline as a Rescue Strategy for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae in Bloodstream Infection: A Retrospective Cohort Study
    Fang, Youling
    Zhong, Qiaoshi
    Chen, Yanhui
    Hang, Yaping
    Fang, Xueyao
    Xiao, Yanping
    Cao, Xingwei
    Zhu, Hongying
    Luo, Hong
    Peng, Suqin
    Gu, Shumin
    Li, Fuxing
    Zhu, Junqi
    Xiong, Jianqiu
    Hu, Longhua
    INFECTION AND DRUG RESISTANCE, 2023, 16 : 2963 - 2971
  • [26] Efficacy of ceftazidime-avibactam in the treatment of carbapenem-resistant Klebsiella pneumoniae infections: Focus on solid organ transplantation recipients
    Hu, Juan
    Zha, Lei
    Yu, Yong-Wei
    Su, Qun
    Fang, Xue-Ling
    Ji, Jin-Ru
    Shen, Ping
    Chen, Yun-Bo
    Zheng, Xia
    Xiao, Yong-Hong
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 63 (05)
  • [27] Efficacy of ceftazidime-avibactam with or without polymyxin for carbapenem-resistant Klebsiella pneumoniae infections after initial treatment with polymyxin
    Lu, Jingli
    Ma, Yani
    Cao, Zhe
    Zhu, Baoling
    Fan, Luna
    Meng, Haiyang
    MICROBIOLOGY SPECTRUM, 2025, 13 (01)
  • [28] Multicenter evaluation of ceftazidime-avibactam use in carbapenem-resistant Klebsiella pneumoniae bloodstream infections in OXA-48 endemic regions
    Mert, Ali
    Derin, Okan
    Akalin, Halis
    Dumlu, Ridvan
    Gundes, Sibel
    Zengin, Rehile
    Kocagoz, Sesin
    Gundogdu, Yasemin
    Koksal, Iftihar
    Yalcin, Demet
    Ustun, Cemal
    Kapmaz, Mahir
    Gorenek, Levent
    Karahangil, Kadriye
    Can, Fusun
    Ergonul, Onder
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [29] Investigation of the synergistic effect of ceftazidime-avibactam and aztreonam combination on carbapenem-resistant Klebsiella pneumoniae isolates with 3 different methods
    Uzunoner, Yasemin
    Kansak, Nilgun
    Aksaray, Sebahat
    ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA, 2024, 71 (04) : 308 - 314
  • [30] Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms
    Temkin, Elizabeth
    Torre-Cisneros, Julian
    Beovic, Bojana
    Benito, Natividad
    Giannella, Maddalena
    Gilarranz, Raul
    Jeremiah, Cameron
    Loeches, Belen
    Machuca, Isabel
    Jose Jimenez-Martin, Maria
    Antonio Martinez, Jose
    Mora-Rillo, Marta
    Navas, Enrique
    Osthoff, Michael
    Carlos Pozo, Juan
    Ramos Ramos, Juan Carlos
    Rodriguez, Marina
    Sanchez-Garcia, Miguel
    Viale, Pierluigi
    Wolff, Michel
    Carmeli, Yehuda
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (02)